Published in Cell Mol Life Sci on May 12, 2016
Novel neurobiological roles of UBE3A. Oncotarget (2017) 0.75
Dysfunctional mTORC1 Signaling: A Convergent Mechanism between Syndromic and Nonsyndromic Forms of Autism Spectrum Disorder? Int J Mol Sci (2017) 0.75
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Arc/Arg3.1 mediates homeostatic synaptic scaling of AMPA receptors. Neuron (2006) 5.48
mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci (2009) 5.04
Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuron (2006) 4.98
Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron (1998) 4.92
Translational control of long-lasting synaptic plasticity and memory. Neuron (2009) 4.77
The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell (2010) 4.72
Synaptic activation causes the mRNA for the IEG Arc to localize selectively near activated postsynaptic sites on dendrites. Neuron (1998) 3.95
Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet (1997) 3.32
Increased expression of the immediate-early gene arc/arg3.1 reduces AMPA receptor-mediated synaptic transmission. Neuron (2006) 2.79
mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66
The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet (2007) 2.60
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57
Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. Nat Neurosci (2007) 2.23
mTORC2 controls actin polymerization required for consolidation of long-term memory. Nat Neurosci (2013) 2.04
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene (2007) 2.03
ADF/cofilin-mediated actin dynamics regulate AMPA receptor trafficking during synaptic plasticity. Nat Neurosci (2010) 1.82
Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. Proc Natl Acad Sci U S A (2010) 1.78
Phosphorylation of protein kinase C-alpha on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase-resistant state. J Biol Chem (1997) 1.56
UBE3A Regulates Synaptic Plasticity and Learning and Memory by Controlling SK2 Channel Endocytosis. Cell Rep (2015) 1.52
Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med (2010) 1.46
The neurology of mTOR. Neuron (2014) 1.43
mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci (2013) 1.43
Analysis of cerebellar function in Ube3a-deficient mice reveals novel genotype-specific behaviors. Hum Mol Genet (2008) 1.37
Autism in Angelman syndrome: implications for autism research. Clin Genet (2004) 1.37
Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology. J Cell Biol (2013) 1.35
Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome. Neurobiol Dis (2010) 1.33
Molecular epigenetics of Angelman syndrome. Cell Mol Life Sci (2007) 1.30
Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res (2013) 1.15
Impairment of TrkB-PSD-95 signaling in Angelman syndrome. PLoS Biol (2013) 1.13
Ampakines promote spine actin polymerization, long-term potentiation, and learning in a mouse model of Angelman syndrome. Neurobiol Dis (2012) 1.08
Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function. J Neurosci (2015) 1.06
Reversal of impaired hippocampal long-term potentiation and contextual fear memory deficits in Angelman syndrome model mice by ErbB inhibitors. Biol Psychiatry (2012) 1.02
Angelman syndrome: current understanding and research prospects. Epilepsia (2009) 1.02
Role of the ubiquitin ligase E6AP/UBE3A in controlling levels of the synaptic protein Arc. Proc Natl Acad Sci U S A (2013) 0.99
Mammalian target of rapamycin and Rictor control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton. Mol Biol Cell (2013) 0.96
Behavioral aspects of Angelman syndrome: a case control study. Am J Med Genet A (2005) 0.95
Dysregulation of mTOR signaling in neuropsychiatric disorders: therapeutic implications. Neuropsychopharmacology (2012) 0.91
Activity-dependent rapid local RhoA synthesis is required for hippocampal synaptic plasticity. J Neurosci (2015) 0.89
Learning and memory: an emergent property of cell motility. Neurobiol Learn Mem (2013) 0.84
In vivo evidence for mTORC2-mediated actin cytoskeleton rearrangement in neurons. Bioarchitecture (2014) 0.80
Potential therapeutic approaches for Angelman syndrome. Expert Opin Ther Targets (2015) 0.77
TORC2: a novel target for treating age-associated memory impairment. Sci Rep (2015) 0.76
Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down's syndrome. Neurobiol Dis (2015) 0.76
Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice. Neuropsychopharmacology (2015) 0.76